HomeAI · summaries
Storia in 8 fonti
Novartis Sees Avidity Drug Fail in Third Setback in a Week
(Bloomberg) -- Novartis AG suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study, raising questions about the drugmaker’s growth prospects.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis RNA drug falls short in rare muscle disease study
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.
- ·
cnbc.com
Pharma major Novartis falls 10% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
